Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 5/20 | 1.00 |
| ▸ | SUZ12 | Q15022 | 5/20 | 1.00 |
| ▸ | EZH2 | Q15910 | 5/20 | 1.00 |
| ▸ | RBBP4 | Q09028 | 1/20 | 1.00 |
| ▸ | RBBP7 | Q16576 | 1/20 | 1.00 |
| ▸ | IDO1 | P14902 | 12/20 | 0.81 |
| ▸ | TDO2 | P48775 | 11/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.63 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | CES2 | O00748 | 1/20 | 0.63 |
| ▸ | APAF1 | O14727 | 1/20 | 0.63 |
| ▸ | TERT | O14746 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16152287 | 1.00 | EED (1.00) | EEDSUZ12EZH2RBBP4RBBP7 | |
| SCHEMBL14417695 | 1.00 | EED (1.00) | EEDSUZ12EZH2RBBP4RBBP7 | |
| SCHEMBL30923422 | 0.90 | IDO1 (1.00) | EEDSUZ12EZH2RBBP4RBBP7 | |
| SCHEMBL20458626 | 0.85 | EED (0.74) | EEDSUZ12EZH2RBBP4RBBP7 | |
| SCHEMBL16152326 | 0.80 | EED (0.78) | EEDSUZ12EZH2RBBP4RBBP7 | |
| Tanshinone Iia SCHEMBL2026738 | 0.77 | EED (1.00) | EEDSUZ12EZH2RBBP4RBBP7 | |
| SCHEMBL30017207 | 0.76 | IDO1 (1.00) | EEDSUZ12EZH2RBBP4RBBP7 | |
| SCHEMBL30978884 | 0.75 | IDO1 (0.61) | EEDSUZ12EZH2RBBP4RBBP7 | |
| SCHEMBL29539317 | 0.75 | IDO1 (0.77) | EEDSUZ12EZH2RBBP4RBBP7 | |
| SCHEMBL16152283 | 0.75 | EED (0.76) | EEDSUZ12EZH2RBBP4RBBP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119380826-B | Chinese patent medicine network pharmacology analysis method and model construction method based on multiscale information entropy | 首都医科大学附属北京朝阳医院 | 2025-04-08 | — | — | CN | disclosed |
| CN-119380826-A | Chinese patent medicine network pharmacology analysis method and model construction method based on multiscale information entropy | 首都医科大学附属北京朝阳医院 | 2025-01-28 | — | — | CN | disclosed |
| CN-119033774-A | KL1333 composition and application thereof in preparation of tumor treatment drugs | 澳门大学 | 2024-11-29 | — | — | CN | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| US-20220175776-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220160664-A1 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | UNITED STATES GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| US-20220127568-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | Frequency Therapeutics, Inc. (US) | 2022-04-28 | — | — | US | disclosed |
| EP-3952854-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20070207989-A1 | DITERPENE DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR, CANCER AND INFLAMMATORY DISEASES | SAVIPU PHARMACEUTICALS (US) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127568-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | WNT3A, WNT1, MECP2 | EED 42/4885SUZ12 113/4885EZH2 14/4885 |
| US-20070207989-A1 | DITERPENE DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR, CANCER AND INFLAMMATORY DISEASES | NFKBIA, EDNRA, EDNRB | EED 2840/4885SUZ12 1953/4885EZH2 4158/4885 |
| US-20220175776-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | HES1, SHH, HDAC11 | EED 1181/4885SUZ12 1115/4885EZH2 90/4885 |
| US-20220160664-A1 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT1, WNT3A, CTNNB1 | EED 524/4885SUZ12 559/4885EZH2 318/4885 |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | OTC, EXOSC5, ENTPD5 | EED 4714/4885SUZ12 4336/4885EZH2 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.